Efficient Attenuation of NK Cell–Mediated Liver Injury through Genetically Manipulating Multiple Immunogenes by Using a Liver-Directed Vector

Adenovirus or adenoviral vectors were reported to induce serious liver inflammation in an NK cell–dependent manner, which limits its clinical applicability for liver gene therapy. We tried to develop an efficient liver-directed therapeutic approach to control hepatic NK cell function via simultaneously manipulating multiple immune genes. Based on our previous study, we found that CCL5 knockdown synergistically enhanced the attenuating effect of silencing CX3CL1 (fractalkine [FKN]) in adenovirus-induced acute liver injury. In addition, the combined treatment of human IL-10 expression with FKN knockdown would further strengthen the protective effect of silencing FKN. We used a hepatocyte-specific promoter to construct a hepatocyte-specific multiple function vector, which could simultaneously overexpress human IL-10 and knock down CCL5 and FKN expression. This vector could attenuate adenovirus-induced acute hepatitis highly efficiently by reducing liver NK cell recruitment and serum IFN-γ and TNF-α. The multiple function vectors could be delivered by nonviral (hydrodynamic injection) and viral (adenovirus) approaches, and maintained long-term function (more than 1 month in mice). Our results suggest a possible strategy to ameliorate the acute liver injury induced by adenovirus by modulating multiple immune genes. The novel multifunction vector has an extensive and practical use for polygenic and complex liver diseases such as malignancies and hepatitis, which correlate with multiple gene disorders.

[1]  J. Gray,et al.  transduction of murine and nonhuman primate liver efficient liver-specific human factor IX expression cassette enable highly Self-complementary adeno-associated virus vectors containing a novel , 2013 .

[2]  R. Flavell,et al.  IL-10 Mediated Regulation of Liver Inflammation during Acute Murine Cytomegalovirus Infection , 2012, PloS one.

[3]  S. Rutz,et al.  Regulation and functions of the IL-10 family of cytokines in inflammation and disease. , 2011, Annual review of immunology.

[4]  Xiaopei Huang,et al.  NKG2D Is Required for NK Cell Activation and Function in Response to E1-Deleted Adenovirus , 2010, The Journal of Immunology.

[5]  Leina Ma,et al.  Potent Antitumor Activity in Experimental Hepatocellular Carcinoma by Adenovirus-Mediated Coexpression of TRAIL and shRNA against COX-2 , 2010, Clinical Cancer Research.

[6]  Dexi Liu,et al.  Progress toward liver‐based gene therapy , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  M. Kay,et al.  Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Xiaopei Huang,et al.  A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  H. Blum.  Molecular therapy and prevention of liver diseases , 2008, Virologica Sinica.

[10]  S. Witting,et al.  Helper-dependent Adenovirus-mediated Short Hairpin RNA Expression in the Liver Activates the Interferon Response* , 2008, Journal of Biological Chemistry.

[11]  Zhigang Tian,et al.  Liver: An organ with predominant innate immunity , 2007, Hepatology.

[12]  R. Sun,et al.  Therapeutic RNA silencing of Cys‐X3‐Cys chemokine ligand 1 gene prevents mice from adenovirus vector‐induced acute liver injury , 2007, Hepatology.

[13]  Geoffrey Kemball-Cook,et al.  Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. , 2006, Blood.

[14]  J. Gingrich,et al.  Oxidative stress is the new stress , 2005, Nature Medicine.

[15]  Patrick J. Paddison,et al.  Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.

[16]  M. Barry,et al.  Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  S. Tschoeke,et al.  Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression. , 2004, Journal of endotoxin research.

[18]  N. Ferry,et al.  Liver gene therapy: advances and hurdles , 2004, Gene therapy.

[19]  R. Sun,et al.  IL-6 Prevents T Cell-Mediated Hepatitis via Inhibition of NKT Cells in CD4+ T Cell- and STAT3-Dependent Manners , 2004, The Journal of Immunology.

[20]  J. Prieto,et al.  Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. , 2004, Gastroenterology.

[21]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[22]  P. Colarusso,et al.  The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. , 2003, Human Gene Therapy.

[23]  J. Prieto,et al.  In vitro and in vivo comparative study of chimeric liver-specific promoters. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  E Marshall,et al.  Gene Therapy Death Prompts Review of Adenovirus Vector , 1999, Science.

[25]  A. Beaudet,et al.  Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Beaudet,et al.  Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. , 1999, Human gene therapy.

[27]  Dexi Liu,et al.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA , 1999, Gene Therapy.

[28]  T. Libermann,et al.  Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. , 1999, Human gene therapy.

[29]  H. Ertl,et al.  Cytotoxic T-Lymphocyte Target Proteins and Their Major Histocompatibility Complex Class I Restriction in Response to Adenovirus Vectors Delivered to Mouse Liver , 1998, Journal of Virology.

[30]  R. Crystal,et al.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. , 1997, Human gene therapy.